touchPODCAST

touchCONGRESS for touchHAEMATOLOGY and touchONCOLOGY

Listen to multiple myeloma expert Dr Rakesh Popat review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the International Multiple Society (IMS) and American Society of Hematology (ASH) 2025 congresses. Dr Popat is then joined by fellow experts Dr Paula Rodríguez-Otero and Dr Roberto Mina to discuss the implications of these data for current and future clinical practice.

Overview

Clinical themes

The internationally renowned multiple myeloma expert faculty

This touchPODCAST is for HCPs outside of the USA. 

This activity is funded by an independent medical education grant from GSK.

This activity is provided by touchIME.

For further information, visit our website: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com

touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY

Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms

In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Nicholas Girard, Institut Curie, Paris, France

Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets

In this module, Professor Pasi Jänne and Dr. Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Module 3: Targeting resistance in EGFR-mutant NSCLC: The role of biomarkers

In this module, Professor Pasi Jänne and Professor Paul Hofman explore how precision medicine and molecular resistance mechanisms are shaping testing strategies. They discuss the role of biomarkers, evolving guideline recommendations and how clinicians can adapt testing approaches to align with new targeted therapies.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Paul Hofman, University Côte d’Azur, Nice, France.

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:  

https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/

https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/

touchEXPERT FOCUS for touchONCOLOGY

Listen to insights from Dr Kathleen Moore on the pathophysiology and molecular features of low-grade serous ovarian cancer (LGSOC) and how it differs from other ovarian cancers. She also discusses evidence-based treatment options and sequencing, as well as practical considerations relating to administration and side-effect management.

The expert:

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from Verastem, Inc.

The activity is jointly provided by Partners for Advancing Clinical Education and touchIME.

For further information visit our website: www.touchONCOLOGY.com

touchIN CONVERSATION for touchHAEMATOLOGY

The presence of anaemia and/or thrombocytopenia complicates the management of patients with myelofibrosis (MF). Listen to expert haematologists consider the burden of cytopenias in patients with MF and discuss strategies to reduce transfusion dependence, improve splenomegaly and personalize treatment with JAK inhibitors.

The experts

This touchPODCAST is for HCPs outside of the USA.

This activity is supported by an independent medical education grant from GSK.

This activity is provided by touchIME in collaboration with our Education Partner Haematology Nurses & Healthcare Professionals Group (HNHCP).

touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchHAEMATOLOGY.com

touchEXPERT FOCUS for touchHAEMATOLOGY and touchONCOLOGY

The experts:

This activity is for healthcare professionals outside of the USA and UK.

touchTALKS for touchONCOLOGY

Listen to Dr Christine Bestvina, as she evaluates the latest data on KRAS mutations in NSCLC and explores how emerging evidence for targeted therapies could influence clinical decision-making.

The expert

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Revolution Medicines.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider. 

For further information visit our website: www.touchONCOLOGY.com

touchEXPERT FOCUS for touchONCOLOGY

Listen to a series of short interviews with four leading experts as they discuss the role of HER2 as a targetable biomarker in BTC and GEA. They examine the present treatment landscape for HER2-positive BTC and GEA and evaluate clinical implications of recent approvals and advances in current and emerging HER2-targeting therapies for HER2-positive BTC and GEA. 

The experts

This touchPODCAST is for HCPs outside of the UK

This activity is supported by an independent educational grant from Jazz Pharmaceuticals. 

Jointly provided by Partners for Advancing Clinical Education and touchIME. 

touchIME is an EBAC® accredited provider. 

For further information visit our website: 

www.touchONCOLOGY.com

touchPANEL DISCUSSION for touchONCOLOGY and touchENDOCRINOLOGY

Listen to a panel of leading experts discuss the optimal management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs), with a focus on peptide receptor radionuclide therapy (PRRT). The faculty provide their insights on the current state of the art, the evolving role of PRRT in GEP-NET treatment, and recent data with existing and emerging PRRT agents. The faculty will also consider future developments in this field, including personalized approaches to PRRT, and how they might impact clinical care.

The experts:

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from ITM Isotope Technologies Munich SE.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our websites: www.touchONCOLOGY.com and www.touchENDOCRINOLOGY.com

touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY

Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms

In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Nicholas Girard, Institut Curie, Paris, France

Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets

In this module, Professor Pasi Jänne and Dr Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:  

https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/

https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/

touchEXPERT FOCUS for touchOPHTHALMOLOGY

Listen to a series of interviews with two medical retina specialists and a biomarker expert who will provide their insights into the pathophysiology of diabetic macular oedema (DMO), including the inflammatory mechanisms of disease and how they may impact treatment. The faculty will also consider the clinical utility of optical coherence tomography (OCT) imaging biomarkers and emerging evidence on the evolving role of corticosteroids in the management of DMO.

The experts:

This touchPODCAST is for HCPs outside of the UK and USA.

This activity is funded by an independent medical education grant from Alimera Sciences Europe Ltd.